NEW KTI/CTI PROJECT FOR ONCOLOGY TARGETS
| Memo Therapeutics AG
Memo Therapeutics AG was awarded a new CTI grant
Memo Therapeutics AG has secured a third CTI project entitled “Novel cell-based immunization technology and functional validation of resulting antibodies” which is intended to complement its MemoMABTM platform with a focus for the discovery of difficult targets such as GPCRs (G Protein-Coupled Receptors). The novel immunization method will be validated through the discovery of antibody portfolios against two novel oncology targets.
For this project MEMO collaborates with ZHAW and two translational oncology groups at Universities of Basel and Bern.